Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.63 |
| ▸ | CTSS | P25774 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567824 | 1.00 | CTSB (0.63) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL3567821 | 1.00 | CTSB (0.63) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL3567830 | 1.00 | CTSB (0.63) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL13544718 | 0.94 | CTSB (0.64) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL3558586 | 0.94 | CTSB (0.64) | CTSBCTSSCYP3A4ADRB3ADRA2B | |
| SCHEMBL8203325 | 0.89 | CTSB (0.50) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3578386 | 0.89 | CTSB (0.50) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3578388 | 0.89 | CTSB (0.50) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL3578393 | 0.89 | CTSB (0.50) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL15705230 | 0.89 | CTSS (0.74) | CTSBCTSSCYP3A4ADRB3ADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365582-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN SCIENCES IRELAND UC (IE) | 2016-06-14 | — | — | US | disclosed |
| US-20140113929-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | Janssen R&D Ireland (formerly Tibotec Pharmaceuticals) (IE) | 2014-04-24 | — | — | US | disclosed |
| US-8637663-B2 | Macrocyclic inhibitors of hepatitis C virus | JANSSEN R&D IRELAND (IE) | 2014-01-28 | — | — | US | disclosed |
| US-20100022578-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100022578-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, HCCS, IFNAR1 | CTSB 2501/4885CTSS 2939/4885CYP3A4 1244/4885 |
| US-20140113929-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | HCCS, HAVCR2, IFNAR1 | CTSB 3016/4885CTSS 3380/4885CYP3A4 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.